|
Secondary prevention
Citations 531-540 of 568 total displayed.
|
Past content
(since Feb 1999):
|
- AHA/AACVPR Scientific Statement
Core Components of Cardiac Rehabilitation/Secondary Prevention Programs : A Statement for Healthcare Professionals From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group
- Gary J. Balady, Philip A. Ades, Patricia Comoss, Marian Limacher, Ileana L. Pina, Douglas Southard, Mark A. Williams, and Terry Bazzarre
Circulation 2000;102:1069-1073
[Full text]
- Clinical Investigations and Reports
Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated?
- Steven A. Grover, Louis Coupal, Hanna Zowall, and Marc Dorais
Circulation 2000;102:722-727
[Abstract]
[Full text]
- Clinical Investigations and Reports
Dose-Finding, Safety, and Tolerability Study of an Oral Platelet Glycoprotein IIb/IIIa Inhibitor, Lotrafiban, in Patients With Coronary or Cerebral Atherosclerotic Disease
- Robert A. Harrington, Paul W. Armstrong, Carmelo Graffagnino, Frans Van de Werf, Dean J. Kereiakes, Kristina N. Sigmon, Tracy Card, Diane M. Joseph, Robert Samuels, Jeffrey Granett, Robert Chan, Robert M. Califf, and Eric J. Topol
Circulation 2000;102:728-735
[Abstract]
[Full text]
- Clinical Investigations and Reports
Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest : The Cardiac Arrest Study Hamburg (CASH)
- Karl-Heinz Kuck, Riccardo Cappato, Jürgen Siebels, and Rudolf Rüppel
Circulation 2000;102:748-754
[Abstract]
[Full text]
- Clinical Investigations and Reports
Effect of Plasma Homocysteine Concentration on Early and Late Events in Patients With Acute Coronary Syndromes
- Peter J. Stubbs, Mohamed K. Al-Obaidi, Ronan M. Conroy, MusB, Paul O. Collinson, MRCPath, Ian M. Graham, FRCPI, and Mark I. M. Noble
Circulation 2000;102:605-610
[Abstract]
[Full text]
- Clinical Investigations and Reports
Inadequate Response to Treatment in Coronary Heart Disease : Adverse Effects of Type D Personality and Younger Age on 5-Year Prognosis and Quality of Life
- Johan Denollet, Johan Vaes, and Dirk L. Brutsaert
Circulation 2000;102:630-635
[Abstract]
[Full text]
- Editorials
Postscripts From the Post Coronary Artery Bypass Graft Trial : The Sustained Benefit of More Aggressive Cholesterol Lowering and the Enigma of Low-Dose Anticoagulation
- David D. Waters and Rabih R. Azar
Circulation 2000;102:144-146
[Full text]
- Clinical Investigations and Reports
Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial
- Genell L. Knatterud, Yves Rosenberg, Lucien Campeau, Nancy L. Geller, Donald B. Hunninghake, Sandra A. Forman, James S. Forrester, Fredarick L. Gobel, J. Alan Herd, Ann Hickey, Byron J. Hoogwerf, Michael L. Terrin, and Carl White
Circulation 2000;102:157-165
[Abstract]
[Full text]
- Editorials
Secondary Prevention of Coronary Heart Disease : The Role of Fibric Acids
- Steven M. Haffner
Circulation 2000;102:2-4
[Full text]
- Clinical Investigations and Reports
Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease : The Bezafibrate Infarction Prevention (BIP) Study
-
Circulation 2000;102:21-27
[Abstract]
[Full text]
|
|
